GlassScriptPhysician profile
Robert P Kelleher
NPI 1891761714
$8,388.30
in general payments reported to CMS, 2019-2025
31 companies · $93.71 in 2025
The $93.71 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,587 · 2020: $659 · 2021: $670 · 2022: $1,515 · 2023: $1,989 · 2024: $874 · 2025: $93.71.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,957.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,957.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,579.10 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Janssen Pharmaceuticals, INC | $820.02 | 2019-2023 | Xarelto |
| Novo Nordisk INC | $711.50 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $595.38 | 2019-2024 | Prolia, Evenity, Otezla |
| Lilly USA, LLC | $577.48 | 2019-2024 | Mounjaro, Jardiance |
| Pfizer INC. | $506.61 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $506.24 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $470.35 | 2019-2024 | Shingrix, Arexvy |
| Abbvie INC. | $437.77 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $338.91 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $325.07 | 2019-2023 | Gardasil 9, Vaxneuvance |
| Amarin Pharma, INC. | $207.04 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $174.57 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $171.44 | 2019-2024 | Eliquis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $138.96 | 2019-2023 | Xifaxan |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $137.17 | 2023 | Myrbetriq, Veozah |
| Tolmar, INC. | $115.19 | 2023-2024 | |
| Idorsia Pharmaceuticals US INC | $110.65 | 2023 | Quviviq |
| Endo Pharmaceuticals INC. | $75.66 | 2019-2022 | |
| Almatica Pharma LLC | $58.30 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $47.63 | 2021-2022 | |
| Abbott Laboratories | $44.26 | 2021-2023 | Freestyle Libre 3 |
| Exact Sciences Corporation | $43.77 | 2023 | Cologuard Collection Kit |
| Acerus Pharmaceuticals Corporation | $37.84 | 2022 | |
| Esperion Therapeutics, INC. | $36.91 | 2021 | |
| Halozyme INC | $33.05 | 2023 | |
| Antares Pharma, INC. | $21.94 | 2019 | |
| Dynavax Technologies Corporation | $17.69 | 2023 | Heplisav-B |
| Sanofi Pasteur INC. | $17.43 | 2022 | |
| Bausch Health US, LLC | $16.10 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $14.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Kelleher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.